Mutational analysis of PhiC31 integrase to improve gene therapeutic applications [Elektronische Ressource] / von Raphael Liesner

icon

142

pages

icon

Deutsch

icon

Documents

2009

Lire un extrait
Lire un extrait

Obtenez un accès à la bibliothèque pour le consulter en ligne En savoir plus

Découvre YouScribe en t'inscrivant gratuitement

Je m'inscris

Découvre YouScribe en t'inscrivant gratuitement

Je m'inscris
icon

142

pages

icon

Deutsch

icon

Ebook

2009

Lire un extrait
Lire un extrait

Obtenez un accès à la bibliothèque pour le consulter en ligne En savoir plus

Max von Pettenkofer-Institut für Hygiene und Medizinische Mikrobiologie Lehrstuhl Virologie Direktor: Prof. Dr. U. Koszinowski Mutational analysis of PhiC31 integrase to improve gene therapeutic applications Dissertation der Fakultät für Biologie der Ludwig-Maximilians-Universität München von Raphael Liesner 1. Dezember 2009 Eingereicht am: 1. Dezember 2009 Erster Gutacher: Prof. Dr. Heinrich Leonhardt Zweiter Gutacher: PD Dr. Berit Jungnickel Sonderberichterstatter: PD Dr. Anja Ehrhardt Tag der mündlichen Prüfung: 2. November 2010 Table of contents Table of contents..........................................................................................................................i List of Tables..............................................................................................................................iv List of Figures ............................................................................................................................. v Abbreviations............................................................................................................................vii Deutsche Zusammenfassung ..................................................................................................... 1 1. Introduction ...........................................................
Voir Alternate Text

Publié le

01 janvier 2009

Nombre de lectures

38

Langue

Deutsch

Poids de l'ouvrage

4 Mo

Max von Pettenkofer-Institut für Hygiene und Medizinische Mikrobiologie
Lehrstuhl Virologie
Direktor: Prof. Dr. U. Koszinowski




Mutational analysis of PhiC31 integrase
to improve gene therapeutic applications


Dissertation
der Fakultät für Biologie
der Ludwig-Maximilians-Universität
München














von
Raphael Liesner


1. Dezember 2009


































Eingereicht am: 1. Dezember 2009

Erster Gutacher: Prof. Dr. Heinrich Leonhardt
Zweiter Gutacher: PD Dr. Berit Jungnickel
Sonderberichterstatter: PD Dr. Anja Ehrhardt

Tag der mündlichen Prüfung: 2. November 2010
Table of contents

Table of contents..........................................................................................................................i

List of Tables..............................................................................................................................iv

List of Figures ............................................................................................................................. v

Abbreviations............................................................................................................................vii

Deutsche Zusammenfassung ..................................................................................................... 1

1. Introduction ............................................................................................................................ 2
1.1 Gene therapy ....................................................................................................................... 2
1.2 Gene transfer systems.......................................................................................................... 4
1.3 Non-viral vectors................................................................................................................. 6
1.3.1 Episomally persisting non-viral vectors........................................................................... 6
1.3.2 DNA recombination-mediated integration and excision by transposases and
recombinases ................................................................................................................. 7
1.4 PhiC31 integrase ............................................................................................................... 12
1.4.1 Recombination and integration efficiency ..................................................................... 12
1.4.2 Integration specificity and aberrant integration events .................................................. 14
1.4.3 Domain organisation and putative protein structure of the PhiC31 integrase................ 16
1.4.4 Applications for PhiC31 integrase ................................................................................. 20
1.4.5 Attempts to improve PhiC31 integrase integration efficacy .......................................... 20
1.5 Aims of this study ............................................................................................................. 22

2. Material ................................................................................................................................. 23
2.1 Laboratory equipment ....................................................................................................... 23
2.2 Chemicals .......................................................................................................................... 23
2.3 Enzymes ............................................................................................................................ 24
2.3.1 Restriction endonucleases .............................................................................................. 24
2.3.2 Other enzymes................................................................................................................ 24
2.4 Solutions, media and buffers............................................................................................. 25
2.4.1 Media, supplements and reagents for eukaryotic cell lines............................................ 27
2.5 Kits .................................................................................................................................... 28
2.6 Organisms.......................................................................................................................... 29
2.6.1 Bacteria........................................................................................................................... 29
2.6.2 Eukaryotic cells .............................................................................................................. 29
2.7 Oligonucleotides................................................................................................................ 30
2.8 Plasmids ............................................................................................................................ 33

i
3. Methods ................................................................................................................................. 35
3.1 General methods with eukaryotic cell culture................................................................... 35
3.1.1 Cultivation of eukaryotic cells ....................................................................................... 35
3.1.2 Storage of eukaryotic cells ............................................................................................. 35
3.1.3 Cell counting of cultured eukaryotic cells...................................................................... 35
3.1.4 Transfection of eukaryotic cells with plasmid DNA...................................................... 35
3.1.5 Transfection with siRNA and plasmid DNA and further applications .......................... 36
3.2 Process to select stable cell lines with integrated plasmid ................................................ 38
3.2.1 Quantification of integration events............................................................................... 39
3.2.2 Establishment of stably transfected cell lines ................................................................ 40
3.2.3 Isolation of genomic DNA from eukaryotic cells .......................................................... 40
3.2.4 Analysis of integration events by plasmid rescue .......................................................... 41
3.2.5 Estimation of the quantity of colonies dependent on the integrase plasmid
concentration ............................................................................................................... 42
3.3 Molecular biology techniques ........................................................................................... 43
3.3.1 Strain cultivation and storage of bacteria....................................................................... 43
3.3.2 Transformation of bacteria ............................................................................................. 43
3.3.3 Preparation of plasmid DNA.......................................................................................... 45
3.3.4 Polymerase chain reaction (PCR)................................................................................... 45
3.3.5 Design of a linker sequence and construction of a cloning vector pCS+NotI ............... 48
3.3.6 Restriction digestion of pDNA and gel electrophoresis................................................. 48
3.3.7 Isolation of DNA fragments from agarose gels ............................................................. 49
3.3.8 Dephosphorylation of DNA fragments .......................................................................... 49
3.3.9 Ligation of DNA fragments and vectors ........................................................................ 49
3.3.10 Determination of DNA concentration .......................................................................... 49
3.3.11 DNA sequencing and DNA alignments ....................................................................... 50
3.3.12 Analysis of RNA, isolation and reverse transcription into cDNA ............................... 50
3.3.13 Quantitative real-time PCR to determine relative DAXX knock down....................... 50
3.4 Fluorescence activated cell sorting (FACS)...................................................................... 51
3.5 Dual luciferase assay......................................................................................................... 52
3.6 Animal studies................................................................................................................... 54
3.6.1 Hydrodynamic tail vein injection................................................................................... 54
3.6.2 Measurement of alanine aminotransferase (ALT).......................................................... 54
3.6.3 Enzyme Linked Immunoabsorbent Assay (ELISA)....................................................... 54

4. Results .............................

Voir Alternate Text
  • Univers Univers
  • Ebooks Ebooks
  • Livres audio Livres audio
  • Presse Presse
  • Podcasts Podcasts
  • BD BD
  • Documents Documents
Alternate Text